Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access
23.4.2026 10:00:00 CEST | Business Wire | Press Release
Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly.
That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions.
The data reveals a structural gap. Although the number of GP facility lenders tracked has more than doubled since 2024, lender appetite remains concentrated around established managers with scale and predictable management fee income. Emerging managers and smaller platforms – those with the greatest need for liquidity – face a materially narrower set of options. Headline willingness to lend to first-time funds stands at 71%, but drops to 46% among lenders operating in the £1m-£5m ticket range, where genuinely emerging managers most commonly sit.
Facilities are underwritten primarily against free cash flow. Where fee coverage is strong, transactions progress smoothly. Where it is thin, deals require more structuring, attract tighter covenants, or fail to clear credit thresholds altogether.
"The supply side has genuinely grown, but where that capital is being deployed tells a different story. Access remains closely tied to scale and track record, which creates real challenges for the managers who need this liquidity the most."
- Edward Beecham, Head of Origination | Fund Finance, Corpay Private Markets
This Lender Book Report is the first edition of the series published under the Corpay Private Markets name, following the acquisition of Alpha Group by Corpay. The full report is available at: https://cb.corpay.com/lender-book-report-h1-2026.
Notes to editors
About the Lender Book Report:
The Lender Book Report is published twice yearly by Corpay Private Markets. It is one of the only reports in the fund finance market based on proprietary transaction data and live lender appetite, rather than survey-based sentiment research. This latest report is the fourth edition in the series.
About Corpay Private Markets:
Corpay Private Markets (formerly Alpha Private Markets), provides a powerful alternative to traditional banking – one that is designed specifically to handle the complexity of private market companies. Combining dedicated teams with purpose-built technologies, we offer a suite of cash and risk management solutions, all seamlessly managed in one place. This includes bank accounts, debt-sourcing, deposit solutions, and multi-bank connectivity, alongside expert advice on managing financial market risks. Corpay Private Markets is part of Corpay, Inc.
Alpha Fund Finance is our specialist fund finance advisory and digital brokerage. Its Alpha Match platform tracks the lending appetite of 500+ active fund finance lenders across subscription lines, NAV facilities, GP financing, and other fund finance products, enabling managers and advisers to efficiently identify the right capital partner for their requirements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260423357040/en/
Contacts
Media enquiries:
Alice Murray, Head of Content: alice.murray@corpay.com
Celine Moran, Account Manager, Liminal PR: celine@liminalcomms.com
Vasiliki Vokou, Account Manager, Liminal PR: vasiliki@liminalcomms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press Release
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. FDA Fast Track designation expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423262096/en/ First
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press Release
Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency with the latest technology. Strategic Partnership with Medfile The joint
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press Release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press Release
Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues, an increase of 8.2% at constant exchange rates (CER) compared to 2024. EBITDA reached €931 million (25.7%). Chiesi closed 2025 with a positive Net Financial Position (cash minus financial liabilities including leasing) of €729 million, improving by €194 million versus 2024, reconfirming the Group’s capacity to self‑finance its investment strategy. The Group’s three therapeutic areas – Respiratory (Air), Rare Diseases (Rare), and Specialty Care (Care) – all contributed well to the year’s sales. A strong performance in the Global Rare Disease business unit saw sales increase to €906 million, +22.3% at CER, representing 50% of total Group growth across the U.S., Europe and international markets. The Air franchise sales reached €1.886 billion, up 3.9% at
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press Release
The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for the year 2024. The Group net profit was at €250.9 million. In 2024, the corresponding figure was €211.1 million. The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposals formulated by the Board of Directors: Authorization to purch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom